In a surprising development, the U.S. Department of Justice filed a brief telling the U.S. Supreme Court that it wants to end a closely watched whistleblower lawsuit filed against Gilead Sciences (GILD) because it is “not in the public interest.”

Moreover, the Justice Department further indicated it would seek to dismiss the case if the Supreme Court were to send it back for further review by a federal circuit court, even though the agency appeared to support the legal theory underpinning the case.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Question to our scribe – what if any action did FDA take against Gilead products in light of the contamination? None that i recall but “who am I?”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy